ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0451

Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort

Murat Torgutalp1, Valeria Rios Rodriguez1, Maryna Verba2, Mikhail Protopopov1, Fabian Proft1, Judith Rademacher1, Hildrun Haibel3, Martin Rudwaleit4, Joachim Sieper3 and Denis Poddubnyy5, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 3Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 5Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

Meeting: ACR Convergence 2021

Keywords: radiography, spondyloarthritis, Spondyloarthropathies, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)

Session Type: Abstract Session

Session Time: 10:00AM-10:15AM

Background/Purpose: Observational cohort studies have shown that there is low, but still detectable progression level in radiographic sacroiliitis, which might also have an impact on the function in patients with axial spondyloarthritis (axSpA). Recent data showed that tumor necrosis factor inhibitors (TNFi) might retard spinal progression when initiated earlier and taken longer in patients with axSpA. However, the question of whether they also have such an effect on radiographic progression in sacroiliac joints (SIJs) is still unclear.

In this study, we aimed to investigate the longitudinal association between radiographic sacroiliitis progression and treatment with TNFi in patients with early axial SpA in a long-term inception cohort.

Methods: Based on the availability of at least two sets of SIJ radiographs, 301 patients (166 with nr-axSpA, symptom duration ≤5 years and 135 with r-axSpA, symptom duration ≤10 years) from the German Spondyloarthritis Inception Cohort (GESPIC) were included in this analysis. These patients contributed with a total of 737 2-year radiographic intervals. Two trained and calibrated central readers scored the radiographs according to the modified New York criteria. If both scored an image as definite radiographic sacroiliitis, the patient was classified as having r-axSpA. The sacroiliac sum score was calculated as a mean of both readers. The association between previous as well as current TNFi use and radiographic sacroiliitis progression, which was defined as the change in the sacroiliitis sum score over 2 years, was analysed using longitudinal generalized estimating equations (GEE) analysis.

Results: At baseline, 9 (3.0%) patients were treated with a TNFi, and 87 (28.9%) patients received at least one TNFi during the entire follow-up period. A total of 141 of the radiographic intervals were covered with TNFi of any duration, while 109 of them were covered with a TNFi of at least 12 months. While receiving ≥12 months TNFi in the previous interval was associated with a lower progression of the sacroiliitis sum score compared to not receiving TNFi in the previous interval, this was not the case in patients who received TNFi ≥12 months in the current 2-year interval (Figure 1). The significant association between TNF ≥12 months in the previous interval and progression in the sacroiliitis sum score were confirmed in the adjusted multivariable longitudinal GEE analysis. In addition, a similar trend for the beneficial effects was observed in different models, which included other treatment definitions with TNFi in the previous 2-year interval (Table).

Conclusion: Treatment with TNFi was associated with retardation of radiographic

Figure. A) Cumulative probability plot of the 2-year progression in the sacroiliitis sum score, stratified by receiving at least 12 months TNFi in the previous and current 2-year radiographic intervals. B) The change in sacroiliitis sum scores over two years in patients with axial spondyloarthritis treated vs non-treated with TNFi at least 12 months in the previous and current 2-year radiographic intervals.

Table. The longitudinal GEE analysis of the association between progression in the sacroiliitis sum score and TNFi use.


M. Torgutalp, None; V. Rios Rodriguez, None; M. Verba, None; M. Protopopov, Novartis, 1, 5, 6; F. Proft, Novartis, 1, 5, 6, Eli Lilly and Company, 1, 5, UCB, 1, 5, 6, AbbVie, 1, 6, Amgen, 1, 6, Bristol-Myers Squibb, 1, 6, Hexal, 1, 6, MSD, 1, 6, Pfizer, 1, 6, Roche, 1, 6; J. Rademacher, None; H. Haibel, Boehringer, 2, Janssen, 2, 6, MSD, 2, 6, Pfizer, 6, Novartis, 2, Roche, 2, 6, AbbVie, 6; M. Rudwaleit, AbbVie, 2, Celgene, 2, Eli Lilly, 2, Janssen, 2, UCB Pharma, 2, AbbVie, 6, Eli Lilly, 6, Novartis, 6, Novartis, 2, UCB Pharma, 6; J. Sieper, AbbVie, 2, 5, 6, Merck, 2, 5, 6, Pfizer, 2, 5, 6, Janssen, 2, 6, Lilly, 2, 6, Novartis, 2, 6, UCB, 2, 6, Roche, 2, 6; D. Poddubnyy, AbbVie, 2, 5, 6, Eli Lilly and Company, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 6, BMS, 2, 6, Roche, 2, 6.

To cite this abstract in AMA style:

Torgutalp M, Rios Rodriguez V, Verba M, Protopopov M, Proft F, Rademacher J, Haibel H, Rudwaleit M, Sieper J, Poddubnyy D. Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/tumor-necrosis-factor-inhibitors-show-a-delayed-effect-on-radiographic-sacroiliitis-progression-in-patients-with-early-axial-spondyloarthritis-10-year-results-from-the-german-spondyloarthritis-incept/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tumor-necrosis-factor-inhibitors-show-a-delayed-effect-on-radiographic-sacroiliitis-progression-in-patients-with-early-axial-spondyloarthritis-10-year-results-from-the-german-spondyloarthritis-incept/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology